Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EO4010 |
Synonyms | |
Therapy Description |
EO4010 is a cancer peptide vaccine composed of bacterial-derived peptides that are homologous to tumor-associated antigens (TAA), which potentially induces an anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EO4010 | EO-4010|EO 4010 | EO4010 is a cancer peptide vaccine composed of bacterial-derived peptides that are homologous to tumor-associated antigens (TAA), which potentially induces an anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05589597 | Phase Ib/II | EO4010 + Nivolumab EO4010 | EO4010 in Previously Treated Metastatic Colorectal Carcinoma (AUDREY) | Active, not recruiting | USA | FRA | ESP | 0 |